Earnings ·
Reports Q3 net loss of $39.7M and extends cash runway into Q4 2027 with $193M in resources
TRDAEntrada Therapeutics, Inc.
Entrada Therapeutics reported a third-quarter net loss of $39.7 million, or $0.94 per share, compared to a $44.1 million loss in the prior-year period. Research and development expenses decreased to $32.4 million from $38.4 million, while general and administrative costs fell slightly to $10.2 million. The company reported collaboration revenue of $0.9 million against $1.6 million previously. Cash, cash equivalents, and marketable securities stood at $193.0 million as of September 30, 2026, providing sufficient funds to operate through the fourth quarter of 2027. Clinically, Cohort 1 data for ELEVATE-45-201 met primary safety objectives, and the company expects further clinical readouts from its Duchenne muscular dystrophy programs in late 2026 and early 2027. Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for neuromuscular and inherited retinal diseases.